Arylsulfatase A pseudodeficiency in healthy Brazilian individuals

C.G. Pedron1,2, P.A. Gaspar1, R. Giugliani1,3 and M.L.S. Pereira1,2

1Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre, 2Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, and 3Departamento de Genética, Instituto de Biociências, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brasil

Abstract

Molecular alterations associated with arylsulfatase A pseudodeficiency (ASA-PD) were characterized by PCR and restriction endonuclease analysis in a sample of healthy individuals from Brazil. ASA activity was also assayed in all subjects. Two individuals homozygous for the N350S and 1524+95A/c174G mutations were detected, corresponding to a frequency of 1.17% (4 of 342 alleles). The individual frequency of the N350S mutation was 20.7% (71 of 342 alleles) and 7.9% (27 of 342 alleles) for the 1524+95A→G mutation. The frequency of the ASA-PD allele in our population was estimated to be 7.9%. This is the first report of ASA-PD allele frequency in a South American population. In addition, the methods used are effective and suitable for application in countries with limited resources. All patients with low ASA activity should be screened for ASA-PD as part of the diagnostic protocol for metachromatic leukodystrophy.

Key words
- Arylsulfatase A
- Pseudodeficiency
- Metachromatic leukodystrophy

Introduction

Arylsulfatase A (ASA, EC 3.1.6.1) is a lysosomal hydrolase that catalyzes the first step in the degradation of cerebroside-3-sulfate, a glycosphingolipid found mainly in the white matter of the central nervous system and in the peripheral nerves (1). The gene coding for human arylsulfatase A maps to the long arm of chromosome 22 and spans 3.2 kb of genomic DNA divided into eight exons. ASA cDNA hybridizes to three different mRNA species and is predicted to code for a protein of 507 amino acids (2).

Mutations in the ASA gene can lead to ASA deficiency, which is associated with two clinical conditions: metachromatic leukodystrophy (MLD) and arylsulfatase A pseudodeficiency (ASA-PD). MLD is a rare lethal neurodegenerative disorder which is inherited as an autosomal recessive trait. MLD patients store sulfatide in their tissues, particularly in the central nervous system. The disease is divided into three clinical forms according to age of onset. MLD-associated mutations have been determined and extensively studied in affected populations (1).

ASA-PD affects healthy individuals, who also show low ASA activity but not sulfatide storage or high excretion of sulfatides in urine. ASA-PD is also caused by alterations in the ASA gene, where A to G transitions are responsible for both an asparagine to serine substitution in exon 6 (termed N350S)
and for the loss of the first polyadenylation signal downstream from the stop codon (termed 1524+95A→G) (3). After characterization of these alterations, simple methods for detecting carriers of these alterations by PCR were developed (4,5).

The identification of the molecular basis for ASA-PD permitted the estimate of the frequency of the PD allele in different populations which was found to range from 6 to 23% (3,6-9). The high frequency of the ASA-PD allele in the general population requires accurate detection of individuals carrying the allele in families at risk for MLD, since the ASA-PD allele is also found in MLD patients (10). The detection of sulfatide storage, which would confirm MLD, is a time-consuming assay. Furthermore, recent data indicate that the detection of the ASA-PD allele is not only important for families at risk for MLD but can be useful for evaluating a possible risk factor for dementia (11).

The data presented here are the first report of ASA-PD allele frequencies in a South American population. We have evaluated the frequency of the N350S and the 1524+95A→G mutations in a healthy Brazilian population, and compared the genotypes determined to ASA activity levels in all individuals.

Material and Methods

Subject samples

The study was approved by the hospital committee on ethical practice and research. Each individual was previously informed of the aims of the study and asked to sign a consent form before sample collection. Blood samples were collected from 171 healthy and unrelated individuals (76 males and 95 females) for both leukocyte preparation (for biochemical analyses) and DNA extraction (for molecular detection of ASA-PD alterations). The ethnic background of the individuals was mixed (predominantly Cauca-
Within each group, samples were subdivided according to gender. A relationship between ASA activity and the different genotypes detected was established and is shown in Figure 2.

The detection of each specific mutation showed that the N350S mutation was present in 71 of the 342 alleles tested, giving a frequency of 20.7%, while the 1524+95A→G mutation was found in 27 of the 342 alleles analyzed, representing 7.9% of the study population.

These data demonstrate the detection of molecular alterations associated with ASA-PD in a healthy Brazilian population. Patient groups C and E, which included individuals carrying the 1524+95A→G mutation, showed lower ASA activities than the other groups. The ASA activities of individuals from group E were similar to the activities found in MLD patients in our laboratory. These results confirm the difficulty of distinguishing individuals who are homozygous for the ASA-PD allele from MLD patients by biochemical methods alone. This is of considerable importance when prenatal diagnosis must be carried out solely by enzyme assay. The storage of sulfatides, which would

![Figure 1](http://example.com/image1)

**Figure 1** - Detection of the N350S and 1524+95A→G mutations. A) Detection of N350S mutation: DNA was amplified by PCR using primers ASA 6i-5' (5' TTATGGCGAACTGACTGAC 3') and ASAp 6i-3' (5' CAGTGCAGG AGGCACCTGAG 3'), products digested with BsrI and fractionated on 2.5% (w/v) agarose gel. Lanes 1 and 3 are homozygotes for the normal sequence; lanes 2 and 4 are heterozygous individuals; lane 5 is a 100-bp DNA ladder. B) Detection of 1524+95A→G mutation. DNA was amplified by PCR using primers ASA E-5' (5' CTGTTCGTGACAAG 3') and ASAp 8i-3' (5' TTCCTATCGTGACCAGG 3'), products digested with DdeI and separated on 3% (w/v) agarose gel. Lane 1 is a 100-bp DNA ladder; lanes 2, 4, 5 and 6 are homozygotes for the normal sequence; lanes 3 and 7 are heterozygous individuals, lane 8 is an individual homozygous for the mutant sequence.

<table>
<thead>
<tr>
<th>Group</th>
<th>Genotypes</th>
<th>No. of subjects</th>
<th>ASA activity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N350S</td>
<td>1524+95A→G</td>
<td>Range</td>
</tr>
<tr>
<td>A</td>
<td>+/-</td>
<td>+/-</td>
<td>104</td>
</tr>
<tr>
<td>B</td>
<td>+/-</td>
<td>+/-</td>
<td>40</td>
</tr>
<tr>
<td>C</td>
<td>+/-</td>
<td>+/-</td>
<td>23</td>
</tr>
<tr>
<td>D</td>
<td>+/-</td>
<td>+/-</td>
<td>2</td>
</tr>
<tr>
<td>E</td>
<td>+/-</td>
<td>+/-</td>
<td>2</td>
</tr>
</tbody>
</table>

Table 1 - Genotypes and ASA activity in different groups of the study population.

α: -/- indicates homozygotes for the normal sequence; +/- indicates heterozygotes; +/- indicates homozygotes for the mutant sequence. b: ASA activities are reported as nmol h⁻¹ mg protein⁻¹. SD = Standard deviation. *P<0.05 compared to groups A and B (ANOVA).
confirm a diagnosis of MLD postnatally, is time-consuming and difficult.

Individuals from group D showed a wide difference in their ASA values and these results were confirmed by two independent assays and reported as the mean value for samples analyzed in duplicate. Therefore, the difference detected is real and shows two extremes of the range. In addition, the values can be compared to the range determined in samples from group B, who share the same molecular alteration (N350S mutation).

When the ASA activities obtained for samples from individuals of different gender within groups A, B and C were compared statistically no difference was observed (data not shown). In addition, when groups A, B and C were compared, group C was found to be different from groups A and B. This analysis confirms data from previous studies which showed that, although the ASA-PD allele carries 2 mutations in the ASA gene, lower ASA activity is primarily the result of the 1524+95A→G mutation.

The overall frequencies of the ASA-PD mutations in our population were 20.7% (71 of 342 alleles) for the N350S mutation and 7.9% (27 of 342 alleles) for the 1524+95A→G mutation. Since in most cases the 1524+95A→G mutation occurs together with the N350S mutation, we can deduce that frequency of the ASA-PD allele in the study population is 7.9%, although a test for the presence of both mutations in the same chromosome was not performed. This frequency lies at the lower end of the frequency range reported for other populations. The subjects were of mixed ethnic origin, although there was a predominance of Caucasian ancestors.

The methods used in this study allowed us to determine the frequency of ASA-PD-associated mutations in our population and to establish a control range for ASA activity in healthy individuals who do not carry ASA-PD-associated mutations (group A). These methods used are effective and easily performed in countries with limited resources. This is important since all patients with low ASA activity should be screened for ASA-PD mutations before a diagnosis of MLD is confirmed and submitted to biochemical investigation complemented by the measurement of urinary sulfatides.

Acknowledgments

The authors are grateful to all volunteers who kindly provided the samples used in this study. The authors would also like to thank Dr. A. Harris for helpful discussion.

References